The focus of the comprehensive in vitro proarrhythmia assay
(CiPA) is on delayed repolarisation and Torsades de Pointes
(TdP) proarrhythmia, a rare but potentially lethal drug-induced
arrhythmia that can lead to ventricular fibrillation and death.
To address limitations with the present approaches, the goal
of CiPA is to provide a new in vitro-based paradigm that
provides a more accurate and comprehensive mechanisticbased
assessment of proarrhythmic liability of evolving drugs.
Gary Gintant, of AbbVie, explains how CiPA is intended to
replace the cumbersome (and expensive) TQT study typically
conducted late in drug development with earlier, mechanisticbased
studies that will include robust preclinical and clinical
assessments.